Latest News

Date Title Topic
21 Feb 2017 Phase II Study Supports Potential for Atezolizumab plus Bevacizumab for Locally Advanced or Metastatic Renal Cell Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
20 Feb 2017 FDA Accepts Two sBLAs for Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
17 Feb 2017 Patient Guide on Glioma Now Available in Italian
17 Feb 2017 Patient Guide on Follicular Lymphoma Now Available in Italian
16 Feb 2017 Press Release: ESMO Supports the 2017 WHO Cancer Resolution Bioethics, legal and economic issues
16 Feb 2017 EU Maltese Presidency on Fairer Pricing for Cancer Drugs Bioethics, legal and economic issues
15 Feb 2017 First-Line Treatment of EGFR and ALK Wild-Type Advanced/Metastatic NSCLC: Refined Endpoints and Statistical Analysis Plan in the Phase III MYSTIC Study Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
14 Feb 2017 European Patent Office Decision on Dasatinib Haematologic malignancies - Anticancer agents & Biologic therapy
14 Feb 2017 ESMO Awards: Now Open for Nominations
13 Feb 2017 Now Available in Polish, the ESMO/ACF Patient Guide on NSCLC
13 Feb 2017 European Commission Approves Pembrolizumab for First-Line Treatment of Patients with Metastatic NSCLC Whose Tumours Have High PD-L1 Expression with No EGFR or ALK Positive Tumour Mutations Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
10 Feb 2017 6th ICHNO Congress: Register now!
10 Feb 2017 Launch of the New Cobas m 511 Analyser Marks a New Era in Haematology Testing Haematologic malignancies
09 Feb 2017 Pre-IMPAKT 2017 Training Course: Apply Today!
09 Feb 2017 Press Release: ESMO Announces New Award for Achievements in Immune-Oncology